About us

SHINKEI is a clinical stage CNS (Central Nervous System) disorders focused pharmaceutical company using the 505(b)2 regulatory strategy to repurpose existing pharmaceutical products for faster and better patient outcome. We have a diversified and robust product development pipeline focus on improving a drug’s administration such that it allows use in indications not previously possible, enhances the convenience, improves compliance, and/or ameliorates the side-effects profile for patients SHINKEI was co-founded by Suresh Borsadia and GP Singh, industry veterans, having the mix of commercial and scientific backgrounds. They are supported by a nimble and efficient team of professionals, advisors and consultants.